Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839429 | 0.79 | BRD4 (0.44) | KMT2A | |
| SCHEMBL321152 | 0.77 | MAPK1 (0.44) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL15167444 | 0.75 | MAPK1 (0.40) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL19409680 | 0.74 | ALDH1A1 (0.43) | ALDH1A1KMT2AHPGD | |
| SCHEMBL186721 | 0.73 | HRH3 (0.51) | MAPK1HRH3ALDH1A1KMT2AHPGD | |
| SCHEMBL1295721 | 0.73 | HRH3 (0.51) | MAPK1HRH3ALDH1A1KMT2AHPGD | |
| SCHEMBL1298062 | 0.73 | HRH3 (0.43) | MAPK1HRH3KMT2ANFKB1NFKB2 | |
| SCHEMBL28492122 | 0.73 | HRH3 (0.51) | MAPK1HRH3ALDH1A1KMT2AHPGD | |
| SCHEMBL34469216 | 0.72 | MAPK1 (0.41) | MAPK1HRH3NFKB1NFKB2RELA | |
| SCHEMBL31506645 | 0.72 | MAPK1 (0.38) | MAPK1HRH3ALDH1A1KMT2ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-115362153-B | Azaspiro compounds as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115066422-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| WO-2021191391-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191390-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021160602-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | WO | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| CN-109715613-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | MAPK1 4510/4885HRH3 3990/4885ALDH1A1 292/4885 |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | MAPK1 4715/4885HRH3 4383/4885ALDH1A1 266/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | MAPK1 4507/4885HRH3 4601/4885ALDH1A1 245/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | MAPK1 4715/4885HRH3 4383/4885ALDH1A1 266/4885 |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | MAPK1 308/4885HRH3 1146/4885ALDH1A1 1045/4885 |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | MAPK1 3834/4885HRH3 3982/4885ALDH1A1 832/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | MAPK1 308/4885HRH3 1146/4885ALDH1A1 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.